Positive results from randomized controlled trial of CP1 01, an oral microbiome drug, for the prevention of recurrent C. difficile infection.-Finch Therapeutics Group
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest